Wave Life Sciences' WVE-006 Achieves MZ-Like Phenotype in AATD Trial, Reducing Harmful Z-AAT by 71%
WVE sits 32% above its 52-week low of $5.02.
Summary
Wave Life Sciences announced highly positive updated data from its RestorAATion-2 Phase 1b/2a trial for WVE-006, its RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The data demonstrated WVE-006 achieved an MZ-like phenotype, generating healthy M-AAT (64% of total AAT) and significantly reducing harmful Z-AAT by 71% in the biweekly cohort, with consistent effects in monthly dosing. The drug was also well-tolerated, showed no liver toxicities, and restored dynamic AAT production, addressing both lung and liver manifestations of AATD. This strong clinical update is highly material for a clinical-stage biotech, indicating significant progress for a key pipeline asset. The company is on track for FDA feedback on a potential accelerated approval pathway by mid-2026, which will be the next major catalyst for the stock.
At the time of this announcement, WVE was trading at $6.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.02 to $21.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.